Detroit、MIにおける転移性癌の臨床試験
Detroitとその周辺地域（約30マイル以内）の拠点で、転移性癌に関する24件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
被験者募集中第2/3相
- Henry Ford Cancer- Detroit, Detroit
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
被験者募集中第3相
- Research Site, Detroit
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
被験者募集中第1/2相
- Henry Ford Cancer Institute, Detroit
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
被験者募集中第1相
- Karmanos Cancer Institute, Detroit
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
被験者募集中第1相
- Barbara Ann Karmanos Cancer Institute, Detroit
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
被験者募集中第3相
- Karmanos Cancer Institute, Detroit
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
被験者募集中第3相
- Karmanos Cancer Institute, Detroit
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
被験者募集中第1/2相
- Clinical Study Site, Detroit
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
被験者募集中第2相
- Henry Ford Cancer Institute/Henry Ford Health System, Detroit
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
被験者募集中第1相
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors
被験者募集中第1/2相
- Crinetics Study Site, Detroit
A Study of ASP1002 in Adults for Treatment of Solid Tumors
被験者募集中第1相
- Henry Ford Hospital, Detroit
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
被験者募集中第1相
- Investigative Site #120, Detroit
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
被験者募集中第1相
- Henry Ford Health System, Detroit
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
被験者募集中第1/2相
- Henry Ford Hospital, Detroit
Laser Interstitial Thermal Ablation and Stereotactic Radiosurgery for Patients With Spine Metastases
被験者募集中
- Henry Ford Hospital, Detroit
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
被験者募集中第1/2相
- Henry Ford Cancer Institute, Detroit
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
被験者募集中第3相
- Henry Ford Health System, Detroit
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
被験者募集中第1/2相
- Karmanos Cancer Institute, Detroit
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
被験者募集中第1/2相
- Karmanos Cancer Institute, Detroit
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
被験者募集中第1相
- Henry Ford Cancer Center, Detroit
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
被験者募集中第1相
- Henry Ford Cancer Institute, Detroit
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
被験者募集中第1相
- Karmanos Cancer Institute, Detroit
A Beta-only IL-2 ImmunoTherapY Study
被験者募集中第1/2相
- Karmanos Cancer Institute, Detroit
他の都市における転移性癌の試験
- Houston, TX104件の研究
- New York City, NY93件の研究
- Nashville, TN70件の研究
- Boston, MA63件の研究
- Los Angeles, CA57件の研究
- St. Louis, MO54件の研究
- Arlington, VA53件の研究
- Philadelphia, PA46件の研究
- Chicago, IL45件の研究
- San Antonio, TX44件の研究
- Washington, DC43件の研究
- Dallas, TX42件の研究
Detroitにおける他の研究
- 非小細胞肺癌44件の研究
- 乳がん33件の研究
- がん（全種類）29件の研究
- 大腸癌26件の研究
- 卵巣がん26件の研究
- 前立腺がん22件の研究
- 子宮内膜がん21件の研究
- 肺がん20件の研究
- 多発性骨髄腫19件の研究
- 胃癌16件の研究
- 頭頸部扁平上皮癌15件の研究
- 急性骨髄性白血病14件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。